BeOne Medicines Ltd. (BeOne, Stock Code: 06160) released its unaudited financial results for the fourth quarter ended December 31, 2025, and audited results for the full year 2025, together with an overview of its upcoming business plans.

In the fourth quarter of 2025, total global revenue reached US$1.50 billion, rising 33% year over year. Global product revenue, representing the vast majority of total revenue, was US$1.48 billion, up 32% over the same period last year. For the full year 2025, total global revenue grew 40% year over year to US$5.30 billion. Global BRUKINSA (zanubrutinib) sales were US$1.10 billion in the fourth quarter, reflecting 38% growth against the prior-year period, and US$3.90 billion for the full year, a 49% increase.

BeOne reported net income of US$66.50 million for the fourth quarter and US$286.93 million for the full year, marking a significant improvement compared to the prior-year periods. Diluted earnings per American Depositary Share (ADS) were US$0.58 in the fourth quarter and US$2.53 for the full year. On a non-GAAP basis, diluted earnings per ADS were US$1.95 for the fourth quarter and US$8.09 for the full year. Free cash flow increased substantially, amounting to US$379.83 million in the fourth quarter and US$941.74 million for the full year.

For 2026, BeOne forecasts total revenue of US$6.20 billion to US$6.40 billion. The company expects its gross margin percentage in the high 80% range and projects GAAP operating income of US$700.00 million to US$800.00 million, alongside non-GAAP operating income of US$1.40 billion to US$1.50 billion.

Recent developments include the strong performance of BRUKINSA in multiple indications, progress on other hematology assets, and continued expansion of TEVIMBRA (tislelizumab). Clinical updates highlighted new indications, priority reviews, and trial initiations across BeOne’s oncology and immunology portfolio.

The announcement also contains forward-looking statements regarding potential product approvals, ongoing research, and commercial plans. According to the published materials, these statements are subject to various risks and uncertainties. BeOne shareholders and potential investors are advised to exercise caution in their dealings in the company’s securities. All figures are presented in U.S. dollars.